Rathbones Group PLC Acquires 12,375 Shares of Guardant Health, Inc. (NASDAQ:GH)

Rathbones Group PLC lifted its holdings in Guardant Health, Inc. (NASDAQ:GH) by 6.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 198,961 shares of the company’s stock after buying an additional 12,375 shares during the quarter. Rathbones Group PLC owned approximately 0.16% of Guardant Health worth $6,078,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Wellington Management Group LLP increased its position in Guardant Health by 188.6% during the 3rd quarter. Wellington Management Group LLP now owns 10,127,528 shares of the company’s stock valued at $232,325,000 after purchasing an additional 6,618,785 shares during the period. Norges Bank bought a new position in Guardant Health in the fourth quarter worth approximately $36,438,000. Lord Abbett & CO. LLC bought a new position in Guardant Health in the third quarter worth approximately $15,624,000. Vanguard Group Inc. lifted its holdings in Guardant Health by 3.0% during the fourth quarter. Vanguard Group Inc. now owns 12,052,551 shares of the company’s stock worth $368,205,000 after buying an additional 350,606 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. boosted its position in Guardant Health by 19.4% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,464,213 shares of the company’s stock valued at $44,732,000 after acquiring an additional 238,037 shares in the last quarter. 92.60% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on GH shares. JPMorgan Chase & Co. increased their target price on shares of Guardant Health from $50.00 to $55.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Stifel Nicolaus boosted their target price on Guardant Health from $45.00 to $53.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Canaccord Genuity Group upped their target price on Guardant Health from $42.00 to $60.00 and gave the company a “buy” rating in a research report on Monday, February 24th. Barclays started coverage on Guardant Health in a report on Thursday, January 23rd. They issued an “overweight” rating and a $60.00 price target for the company. Finally, Stephens reissued an “overweight” rating and set a $55.00 target price on shares of Guardant Health in a research report on Wednesday, March 26th. Twenty equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $48.95.

Guardant Health Price Performance

Shares of GH opened at $41.78 on Tuesday. Guardant Health, Inc. has a 1-year low of $15.81 and a 1-year high of $50.89. The stock has a market cap of $5.16 billion, a price-to-earnings ratio of -11.74 and a beta of 1.45. The firm has a 50 day simple moving average of $44.28 and a 200-day simple moving average of $35.07.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15). The firm had revenue of $201.81 million during the quarter, compared to analyst estimates of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. On average, equities analysts expect that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.